- Formylated chloro-bridged iridium(iii) dimers as OLED materials: Opening up new possibilities
-
In this study, a series of four formyl-substituted chloro-bridged iridium(iii) dimers were prepared. Their absorption, photophysical and electrochemical properties were studied in dichloromethane solution. It was found that as the formyl content increased on the cyclometalating ligands, emission unexpectedly became brighter. Organic light-emitting diodes (OLEDs) were fabricated using each of these iridium dimers as the emitter. The OLED fabricated using the brightest of the series, 2b, as the dopant afforded a decent external quantum efficiency (EQE) of 2.6%. This suggests that chloro-bridged iridium dimers are potential candidates as solid-state emitters. This journal is
- Wong, Michael Y.,Xie, Guohua,Tourbillon, Clarisse,Sandroni, Martina,Cordes, David B.,Slawin, Alexandra M. Z.,Samuel, Ifor D.W.,Zysman-Colman, Eli
-
-
Read Online
- MATRIX METALLOPROTEINASE INHIBITORS
-
The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over- activation of a matrix metalloproteinase using the compounds.
- -
-
Page/Page column 89
(2008/06/13)
-